Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is implicated in humans in Th2-dependent allergic inflammation.

About Panmira

Founded in 2011 and headquartered in San Diego, Panmira Pharmaceuticals, LLC is a small molecule pharmaceutical company focused on partnering clinical candidates for inflammatory diseases.  Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb. For more information, visit www.panmira.com.


'/>"/>
SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017  Rigel Pharmaceuticals (Nasdaq: ... and January 16, 2017 the Compensation Committee of Rigel,s ... options to purchase an aggregate of 214,000 shares of ... granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, ... employees entering into employment with Rigel, in accordance with ...
(Date:1/15/2017)... 14, 2017 ImmersiveTouch Inc., the global leader ... announced recent appointments strengthening their Executive Management team.  ... as Chief Executive Officer, Jay Banerjee as ... President of Sales and Jia Luo , PhD ... Mr. Bowman has 20 years experience commercializing ...
(Date:1/13/2017)... 13, 2017 Constant research ongoing in ... collectively contribute to the demand for western blotting technique. The ... of US$ 551.0 Mn by 2016 end. Developing economies in ... lucrative markets for western blotting, whereas North America ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... organized to provide first-quality education and high-level training standards to an international multidisciplinary ... of eating disorder problems. As a way to further its mission at the ...
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s ... the field of midmarket financial software. , Members of the VAR Stars were selected ... based on revenue and those firms chosen represent a wide range of size and ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... has achieved accreditation for its specialty care services. Albertsons Companies is the ... specialty care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ ...
(Date:1/15/2017)... ... , ... The Gravity Vault Indoor Rock Climbing Gym is excited to announce ... the 14,000+ square foot climbing gym, the owners anticipate to open sometime in February ... and two in New York. With this being its first location in Pennsylvania, The ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products and ... Emoji Scale is now available on Apple as a fun, free emoji sticker pack ... choosing one of the ten color coded values on The Emoji Scale. , ...
Breaking Medicine News(10 mins):